CHD1 and neoplasm: CHD1 loss has previously been found to be enriched in mCRPC patients with primary resistance to abiraterone and enzalutamide based on analysis of circulating tumor cells [57], and low CHD1 expression has been reported to be associated with shorter response to enzalutamide but not abiraterone [58].